Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus

被引:108
作者
Leahy, Jack L. [1 ,2 ]
Hirsch, Irl B. [3 ,4 ]
Peterson, Kevin A. [5 ]
Schneider, Doron [6 ,7 ]
机构
[1] Univ Vermont, Coll Med, Endocrinol Diabet & Metab Unit, Colchester, VT 05446 USA
[2] Vermont Reg Diabet Ctr, S Burlington, VT 05403 USA
[3] Univ Washington, Sch Med, Seattle, WA 98195 USA
[4] Diabet Care Ctr, Seattle, WA 98105 USA
[5] Univ Minnesota, Sch Med, Dept Family Med & Community Hlth, Minneapolis, MN 55455 USA
[6] Drexel Univ, Philadelphia, PA 19104 USA
[7] Abington Mem Hosp, Ctr Patient Safety & Healthcare Qual, Abington, PA 19001 USA
关键词
GLUCAGON-LIKE PEPTIDE-1; IMPAIRED GLUCOSE-TOLERANCE; INTENSIVE INSULIN THERAPY; TERM GLYCEMIC CONTROL; INTRAVENOUS GLUCOSE; LIFE-STYLE; INHIBITOR VILDAGLIPTIN; TREATED PATIENTS; ENERGY-INTAKE; IV INHIBITOR;
D O I
10.1210/jc.2010-0668
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objective: This report examines current perspectives regarding likely mechanisms of beta-cell failure in type 2 diabetes and their clinical implications for protecting or sparing beta-cells early in the disease progression. In addition, it considers translation strategies to incorporate relevant scientific findings into educational initiatives targeting clinical practice behavior. Participants: On January 10, 2009, a working group of basic researchers, clinical endocrinologists, and primary care physicians met to consider whether current knowledge regarding pancreatic beta-cell defects justifies retargeting and retiming treatment for clinical practice. Based on this meeting, a writing group comprised of four meeting participants subsequently prepared this consensus statement. The conference was convened by The Endocrine Society and funded by an unrestricted educational grant from Novo Nordisk. Evidence: Participants reviewed and discussed published literature, plus their own unpublished data. Consensus Process: The summary and recommendations were supported unanimously by the writing group as representing the consensus opinions of the working group. Conclusions: Workshop participants strongly advocated developing new systems to address common barriers to glycemic control and recommended several initial steps toward this goal. These recommendations included further studies to establish the clinical value of pharmacological therapies, continuing basic research to elucidate the nature and mechanisms of beta-cell failure in type 2 diabetes mellitus, and exploring new educational approaches to promote pathophysiology-based clinical practices. The Endocrine Society has launched a new website to continue the discussion between endocrinologists and primary care physicians on beta-cell pathophysiology in type 2 diabetes and its clinical implications. Join the conversation at http://www.betacellsindiabetes.org (J Clin Endocrinol Metab 95: 4206-4216, 2010)
引用
收藏
页码:4206 / 4216
页数:11
相关论文
共 121 条
[1]
The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance [J].
Abdul-Ghani, Muhammad A. ;
Matsuda, Masafumi ;
Jani, Rucha ;
Jenkinson, Christopher P. ;
Coletta, Dawn K. ;
Kaku, Kohei ;
DeFronzo, Ralph A. .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2008, 295 (02) :E401-E406
[2]
Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells [J].
Abraham, EJ ;
Leech, CA ;
Lin, JC ;
Zulewski, H ;
Habener, JF .
ENDOCRINOLOGY, 2002, 143 (08) :3152-3161
[3]
Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year [J].
Ahrén, B ;
Pacini, G ;
Foley, JE ;
Schweizer, A .
DIABETES CARE, 2005, 28 (08) :1936-1940
[4]
Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis [J].
Amori, Renee E. ;
Lau, Joseph ;
Pittas, Anastassios G. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02) :194-206
[5]
[Anonymous], P 68 ANN M AM DIAB A
[6]
Deteriorating beta-cell function in type 2 diabetes: a long-term model [J].
Bagust, A ;
Beale, S .
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2003, 96 (04) :281-288
[7]
TOWARD PHYSIOLOGICAL UNDERSTANDING OF GLUCOSE-TOLERANCE - MINIMAL-MODEL APPROACH [J].
BERGMAN, RN .
DIABETES, 1989, 38 (12) :1512-1527
[8]
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes [J].
Blonde, L. ;
Klein, E. J. ;
Han, J. ;
Zhang, B. ;
Mac, S. M. ;
Poon, T. H. ;
Taylor, K. L. ;
Trautmann, M. E. ;
Kim, D. D. ;
Kendall, D. M. .
DIABETES OBESITY & METABOLISM, 2006, 8 (04) :436-447
[9]
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury [J].
Bose, AK ;
Mocanu, MM ;
Carr, RD ;
Brand, CL ;
Yellon, DM .
DIABETES, 2005, 54 (01) :146-151
[10]
The burden of treatment failure in type 2 diabetes [J].
Brown, JB ;
Nichols, GA ;
Perry, A .
DIABETES CARE, 2004, 27 (07) :1535-1540